Scholarlink

Background <p>Glucagon-like peptide-1 (GLP-1) receptor agonists have metabolic and hepatic benefits in metabolic dysfunction–associated steatotic liver disease (MASLD), but their additive benefit compared to lifestyle modification only in real-world settings remains uncertain. This study compared the effects of GLP-1 agonist therapy and physical activity on body mass index (BMI) and noninvasive liver metrics in a predominantly Hispanic clinical population with MASLD.</p> Methods <p>This is a retrospective longitudinal study of 202 adults with MASLD evaluated at an outpatient gastroenterology clinic. BMI, controlled attenuation parameter (CAP), liver stiffness (kPa), and Fibrosis-4 (FIB-4) indices were analyzed at baseline and follow-up (1–2 years). Primary analyses compared follow up outcomes between GLP-1 therapy and an unmonitored physical activity comparator group; exploratory analyses assessed whether effects differed by sex or ethnicity.</p> Results <p>Among 193 patients with complete BMI data and 131 with liver metrics, GLP-1 agonist therapy was associated with a greater reduction in BMI (–1.47&#xa0;kg/m²; 95% CI, − 2.54 to − 0.41; <i>p</i> = 0.007) and in FIB-4 indices (–0.29; 95% CI, − 0.56 to − 0.03; <i>p</i> = 0.029) compared with physical activity only. Adjusted differences in CAP (–3.31 dB/m) and liver stiffness (+ 0.01&#xa0;kPa) were not statistically significant.</p> Conclusion <p>In this real-world MASLD cohort, GLP-1 therapy was associated with greater baseline-adjusted improvements in BMI and FIB-4 compared with physical activity alone, while CAP and liver stiffness were not statistically significant. These findings provide supportive real-world evidence for GLP-1 associated metabolic benefit and warrant confirmation of hepatic effects in larger prospective studies, including cohorts with substantial Hispanic representation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Jason N. Chen,
  • Bulent Tolga Delibasi,
  • James Wang,
  • Thomas Tran,
  • Connie Hu,
  • Charles W. Randall

摘要

Background

Glucagon-like peptide-1 (GLP-1) receptor agonists have metabolic and hepatic benefits in metabolic dysfunction–associated steatotic liver disease (MASLD), but their additive benefit compared to lifestyle modification only in real-world settings remains uncertain. This study compared the effects of GLP-1 agonist therapy and physical activity on body mass index (BMI) and noninvasive liver metrics in a predominantly Hispanic clinical population with MASLD.

Methods

This is a retrospective longitudinal study of 202 adults with MASLD evaluated at an outpatient gastroenterology clinic. BMI, controlled attenuation parameter (CAP), liver stiffness (kPa), and Fibrosis-4 (FIB-4) indices were analyzed at baseline and follow-up (1–2 years). Primary analyses compared follow up outcomes between GLP-1 therapy and an unmonitored physical activity comparator group; exploratory analyses assessed whether effects differed by sex or ethnicity.

Results

Among 193 patients with complete BMI data and 131 with liver metrics, GLP-1 agonist therapy was associated with a greater reduction in BMI (–1.47 kg/m²; 95% CI, − 2.54 to − 0.41; p = 0.007) and in FIB-4 indices (–0.29; 95% CI, − 0.56 to − 0.03; p = 0.029) compared with physical activity only. Adjusted differences in CAP (–3.31 dB/m) and liver stiffness (+ 0.01 kPa) were not statistically significant.

Conclusion

In this real-world MASLD cohort, GLP-1 therapy was associated with greater baseline-adjusted improvements in BMI and FIB-4 compared with physical activity alone, while CAP and liver stiffness were not statistically significant. These findings provide supportive real-world evidence for GLP-1 associated metabolic benefit and warrant confirmation of hepatic effects in larger prospective studies, including cohorts with substantial Hispanic representation.